Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial.

Détails

Ressource 1Télécharger: 29644007_BIB_289EF15FCDC6.pdf (3123.36 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_289EF15FCDC6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial.
Périodique
Oncotarget
Auteur(s)
Bourgier C., Castan F., Riou O., Nguyen T.D., Peignaux K., Lemanski C., Lagrange J.L., Kirova Y., Lartigau E., Belkacemi Y., Rivera S., Noël G., Clippe S., Mornex F., Hennequin C., Gourgou S., Brengues M., Fenoglietto P., Ozsahin E.M., Azria D.
ISSN
1949-2553 (Electronic)
ISSN-L
1949-2553
Statut éditorial
Publié
Date de publication
20/03/2018
Peer-reviewed
Oui
Volume
9
Numéro
21
Pages
15757-15765
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay).
HT <sup>-</sup> and RILA <sup>high</sup> were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILA <sup>low</sup> and HT <sup>+</sup> than in patients with RILA <sup>high</sup> and HT <sup>-</sup> (75.8% and 100%, respectively; <i>p</i> = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8-19.1]). Conversely, BFFS at 36 months was comparable in patients with RILA <sup>high</sup> and HT <sup>+</sup> and in patients with RILA <sup>low</sup> and HT <sup>-</sup> (89.8% and 93.5%, respectively; <i>p</i> = 0.39, hazard ratio 1.7 [95% CI 0.51-5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy).
HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILA <sup>high</sup> and HT <sup>-</sup> presented an excellent BFFS at 36 months (100%).
Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT <sup>+</sup> and HT <sup>-</sup> , respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILA <sup>low</sup> ; ≥12%: RILA <sup>high</sup> ).

Mots-clé
breast cancer, hormonotherapy, individual radiosensitivity, late effects, radiotherapy
Pubmed
Open Access
Oui
Création de la notice
19/04/2018 20:06
Dernière modification de la notice
20/08/2019 13:08
Données d'usage